Aeglea BioTherapeutics Investor Presentation Deck

Combination programs summary SPYRE 1000 COMBINATION OF POTENTIALLY BEST-IN-CLASS MONOTHERAPY BUILDING BLOCKS HI TARGETING UNIFIED Q8-12W DOSING FOR OPTIMIZED PATIENT CONVENIENCE DEVELOPING PATIENT SELECTION APPROACHES TO IDENTIFY RESPONDERS SPY130 Phase 2 study initiation expected in 2025 32

View entire presentation